Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia
Authors' conclusion
Based on nocturnal plasma glucose measurements, treatment with insulin degludec compared with insulin glargine U100 administered in the evening results in lower glycaemic variability and lower risk of nocturnal hypoglycaemia without differences in mean plasma glucose.
Study context
- Population
- People with T1D prone to nocturnal severe hypoglycaemia; substudy participants stayed at least one night in hospital during each treatment for hourly plasma glucose samplingsubstudy of 149 randomized
- Participants
- 51 people
- Comparison
- Insulin degludec vs insulin glargine U100
- Primary endpoint
- Nocturnal glucose profiles, incl. mean plasma glucose, glycaemic variability and risk of hypoglycaemia
Methodological detailsinvestigator-initiated, crossover, predefined substudy
- Investigator-initiated
- Crossover
- Predefined substudy
Primary result
As reported in the abstract
Nocturnal plasma glucose profiles
Insulin degludec vs Insulin glargine U100Estimated treatment difference, % (95% CI)P value
Glycaemic variability; lower with degludec
−4.3(−8.1 to −0.5)
P < 0.05Insulin degludec vs Insulin glargine U100Hazard ratio (95% CI)P value
Nocturnal hypoglycaemia <3.0 mmol/L
0.36(0.17–0.73)
P < 0.05Original publication
Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia. Diabetes Obes Metab. Published 28 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →